Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Portal Biotechnologies›
News
AddedJun 25, 2026
UpdatedJun 25, 2026
Portal Biotechnologies

Portal Biotechnologies

Series A

Portal Biotechnologies is a Watertown, Massachusetts-based cell engineering and drug discovery platform company founded in 2023.

HQ
Watertown, MA, US
Founded
2023
Loading
Overview
Analysis
Compare
Fundraising
Employees
News

Latest News About Portal Biotechnologies

Portal Biotechnologies Raises $9M in Funding

FinSMEs

Portal Biotechnologies Raises $9M in Funding

Portal Biotechnologies, a Watertown, MA-based cell engineering and drug discovery platform, raised $9M in an oversubscribed round led by...

Jun 19, 2026

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Business Wire

Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers

Portal Biotechnologies announced an oversubscribed $9M round led by NFX, an expanded DARPA contract, and more than 100 customers across top...

Jun 18, 2026

Portal Biotechnologies Awarded $8M DARPA Contract to Increase Access to Cell Therapy via a Portable, Red Blood Cell Engineering Device for Rapid Point-of-Care Production and Treatment

Business Wire

Portal Biotechnologies Awarded $8M DARPA Contract to Increase Access to Cell Therapy via a Portable, Red Blood Cell Engineering Device for Rapid Point-of-Care Production and Treatment

Portal Biotechnologies was awarded an $8M DARPA contract to develop a portable, field-deployable red blood cell engineering device for...

Jun 24, 2025

Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures

Business Wire

Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures

Portal Biotechnologies announced more than 50 biopharma and academic partnerships and an oversubscribed $7M seed round led by IA Ventures...

Dec 19, 2024

Former SQZ Biotech CEO Armon Sharei Launches Portal, A Cell-Therapy Tools Company

Boston Business Journal

Former SQZ Biotech CEO Armon Sharei Launches Portal, A Cell-Therapy Tools Company

Boston Business Journal profiles Portal Biotechnologies founder and CEO Armon Sharei, former SQZ Biotechnologies CEO, on the launch of a...

Dec 21, 2023

Introducing Portal Biotechnologies: A New Cell Engineering Platform, Gateway, Offers Scalable Delivery of Diverse Payloads for Cell Therapy, Immunotherapy, and Beyond

Business Wire

Introducing Portal Biotechnologies: A New Cell Engineering Platform, Gateway, Offers Scalable Delivery of Diverse Payloads for Cell Therapy, Immunotherapy, and Beyond

Portal Biotechnologies launched from stealth with its Gateway cell engineering platform, enabling scalable, high-throughput intracellular...

Dec 12, 2023